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 ‘ ’HIV infection and AIDS is growing -  but so too is public 
apathy. We have already lost too many friends and 
colleagues’’ 
David Geffen 
 
 
 
‘ ’The greatest grand challenge for any scientist is 
discovering how to prevent the spread of HIV and finding 
the cure or an effective vaccine for AIDS’’ 
Philip Emeagwali 
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Abstract: 
 
Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) comprises 
the use of antiretroviral medications by HIV negative individuals to decrease infection 
risk. Men who have sex with men (MSM) have higher rates of HIV infection. Among 
MSM, migrants may face additional barriers related to certain types of cultures and 
stigma when seeking medical counseling that may increase the risk of acquiring the 
infection. This indicates an urgent need to develop alternative HIV prevention 
strategies. PrEP is a promising approach that can be part of an optimal 
comprehensive HIV prevention package targeted toward MSM in Portugal. This 
present study aims to estimate the proportions of eligible individuals for PrEP among 
a sample of 3 categories: 1) Portuguese-born living in Portugal, 2) non-Portuguese-
born living in Portugal, and 3) Portuguese-born living abroad. Furthermore, it aims to 
identify predictors of eligibility in each group. This study was conducted among the 
Portuguese sample of The European Men-who-have-Sex-With-Men Internet Survey 
(EMIS), a cross sectional study that took place from June to August 2010. The 
sample included 5187 participants living in Portugal (80.7% Portuguese-born and 
17.4% migrants) and 375 Portuguese-born living abroad (representing 8.1% of 
Portuguese-born and now living in other EMIS countries). Migrants were defined as 
men who were born in other country than their current country of residence. 
Information on HIV status, socio-demographic and behavioral characteristics was 
collected. Eligibility for PrEP was estimated according to the guidelines of the 
Centers for Disease Control and Prevention.  Proportions were compared using the 
Chi-squared test and Odds Ratios (OR) with 95% confidence interval (95% CI) were 
computed using logistic regression to determine the predictors of PrEP at each 
group. The study found similar proportions of MSM eligible for PrEP among migrants 
living in Portugal (46.3%), Portuguese-born living in Portugal (44.4%) and 
Portuguese-born living abroad (45.1%) (p=0.621). Among migrants living in Portugal, 
participants from Latin America and the Caribbean region origin were more likely to 
be eligible for PrEP in comparison to Portuguese-born. The predictors of eligibility for 
PrEP were different among the 3 groups. Additional safe and effective approaches 
for HIV prevention in MSM such as PrEP are urgently needed. 
 
KEYWORDS:  
HIV, Pre-Exposure prophylaxis, MSM, Migrants 
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Resumo 
A profilaxia pré-exposição (PrEP) para o VIH compreende o uso de medicamentos 
antirretrovíricos por indivíduos VIH negativos para diminuir o risco de infeção. Os 
homens que têm sexo com homens (HSH) têm maiores taxas de infeção por VIH. 
Entre os migrantes HSH, certos tipos de culturas, estigma e barreiras ao acesso ao 
aconselhamento médico, pode aumentar o risco de adquirir a infeção. Isto indica 
uma necessidade urgente de desenvolver estratégias alternativas de prevenção do 
VIH. A PrEP é uma abordagem promissora que pode ser utilizada como parte de 
uma estratégia abrangente de prevenção para o  VIH dirigida aos  HSH em Portugal. 
O presente estudo teve como objetivo estimar a proporção de indivíduos elegíveis 
para PrEP em três grupos:  1) nascidos e residentes em Portugal 2) nascidos noutro 
país e residentes em Portugal, e 3) nascidos em Portugal e residentes  no 
estrangeiro. Para além disto, pretendeu-se identificar os preditores de elegibilidade 
em cada grupo. Para este estudo utilizaram-se dados da amostra portuguesa do 
estudo EMIS - European Men-who-have-sex Internet survey, um estudo transversal 
que teve lugar no período de junho a agosto de 2010. A amostra incluiu 5.187 
participantes residentes  em Portugal (80,7% nasceram em Portugal, 17,4% 
nasceram noutro país) e 375 indivíduos nascidos em Portugal residentes no 
estrangeiro (representando 8,1% dos HSH nascidos em Portugal e agora vivendo 
em outros países EMIS). Definiu-se como migrante os homens que nasceram num 
país diferente do seu país de residência atual. Recolheu-se informação sobre o 
estatuto serológico VIH, características sóciodemográficas e comportamentais. A 
elegibilidade para PrEP foi estimada de acordo com as orientações do Centro para o 
Controlo e Prevenção de Doenças dos Estados Unidos. Para comparar as 
proporções utilizou-se o teste do qui-quadrado e para determinar os preditores de 
profilaxia pré-exposição em cada grupo calcularam-se Odds Ratio (OR) com 
intervalos de confiança de 95% (IC95%) utilizaram-se modelos de regressão 
logística.. Encontraram-se proporções semelhantes de HSH elegíveis para PrEP 
entre os migrantes que vivem em Portugal (46,3%), os nascidos e residentes em 
Portugal (44,4%) e os migrantes nascidos em Portugal (45,1%) (p=0,621). Nos 
migrantes que vivem em Portugal, os participantes de origem região das Caraíbas e 
da América Latina eram mais provavelmente elegíveis para a PrEP em comparação 
com os nascidos em Portugal. Os preditores de elegibilidade para PrEP foram 
diferentes entre os três grupos. Abordagens seguras e eficazes adicionais para a 
prevenção do VIH em HSH, como PrEP são urgentemente necessários. 
 
PALAVRAS-CHAVE: 
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INTRODUCTION 
 
Human immunodeficiency virus (HIV) infection prevention had rapidly developed 
over the last decade, with several large-scale research studies and clinical trials 
showing that antiretrovirals (ARVs) can be used not only for the prevention of 
mother-to-child transmission, post-exposure prophylaxis and treatment as prevention 
(TasP) but also as HIV pre-exposure Prophylaxis (PrEP). 
 
Daily oral PrEP with Tenofovir Disoproxil Fumarate-Emtricitabine (TDF–FTC) can 
safely and effectively reduce the risk of HIV infection among the not infected MSM 
and among heterosexual women and men. The recent Food and Drug Administration 
(FDA) approval for the use of Truvada® to prevent the acquisition of HIV infection 
and the release of interim guidance by the Centers for Disease Control and 
Prevention (CDC) for PrEP in men who have sex with men (MSM) (1) and 
heterosexually active individuals (2) ,at high risk of acquiring HIV, have increased the 
awareness and interest in PrEP as an important new addition to HIV infection 
prevention services. 
 
On the other hand, and since the early beginning of the disease, MSM have been a 
core population affected by HIV infection (3). In spite of decades of public health 
efforts, in addition to community, medical and epidemiological research, HIV 
prevalence and incidence is still high and represent a heavy burden in MSM 
throughout the world(4). Even in high-income countries, the general HIV epidemic is 
declining except in MSM(5). Several factors play a role in aggravating the infection 
within the MSM community, starting from the biological factors, the stigma of the 
homosexuality and the denial of health services for MSM in several settings across 
the world, depriving them from the access to most of the basic HIV services and 
counseling (6).  
 
Moreover, although several studies state about the relation between migration and 
HIV (7-11), there are only a few studies that showed in depth analysis or estimated 
the effect of the socio cultural effect in being involved in sexual risk behaviors in 
migrants MSM. 
 
All of that make the recent optimism, that prevention methods such as the biomedical 
intervention chemoprophylaxis using a combination of TDF and FTC (Truvada®) 
having efficacy for MSM of paramount importance (12), and starts up real 
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opportunities for controlling the epidemics of HIV in MSM (6),  bearing in mind that if 
we are aiming to achieve control of HIV infection, no population at high risk of 
infection can be excluded and no single HIV prevention strategy is going to be 
effective alone, knowing that several studies proved the cost effectiveness of PrEP in 
high epidemic settings (13). 
 
As recently as 2012, Portuguese surveillance data reported that MSM in Portugal 
accounted for 24% of new HIV infection although representing only 3% of the 
Portuguese adult population (14). In addition, and according to national HIV 
prevalence data, the prevalence of HIV in MSM is around 11% among those ever 
tested (15). This data confirm that existing approaches to prevention have failed to 
control the HIV epidemic among MSM. A recent study, the iPrEX study, suggests 
that chemoprophylaxis PrEP could be a promising and effective approach to reduce 
the incidence of HIV in the MSM population. The study showed that a daily dose of 
TDF/FTC decreased HIV incidence in MSM (12) by 44% in general and by 73% 
among those who were highly adherent to daily dose. This suggests that HIV PrEP 
could have a potential role to effectively reduce the HIV epidemic in Portugal, where 
MSM have the highest annual incidence among all high-risk groups. 
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STATEMENT OF THE PROBLEM AND SIGNIFICANCE OF THE STUDY 
 
In comparison to the current prevention methods such as condom use, lubricants, 
HIV voluntary counseling and testing, PrEP is an additional effective intervention, 
which had shown efficacy against HIV infection in MSM. Therefore detecting the 
prevalence and predictors of eligibility for HIV PrEP in the Portuguese sample of the 
European Men Who Have Sex with Men Internet Survey (EMIS), the largest sample 
of MSM ever studied in Portugal, will help us to better understand the magnitude of 
the problem prior to its adoption as a new effective HIV preventive method in 
Portugal. The study’s significance lies in adding to efforts in controlling and curbing 
the spread and the rise in HIV infections at one of the most at high-risk population as 
well as detecting the determinants of being eligible for a new prevention method as 
PrEP in Portugal. This research is intended to add to the body of knowledge on PrEP 
in the Portuguese context. Moreover, it aims to stimulate more research and studies 
prior the adoption of PrEP in Portugal. 
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THEORETICAL BACKGROUND 
Introduction 
 
After more than thirty years of the first description of the HIV in MSM, the worldwide 
community is confronting a re-emerging and recent documented HIV epidemic 
among this population (16, 17). There is a need to start and scale up comprehensive 
sustained and effective HIV prevention methods among MSM in both the developing 
and the developed world. This goal can be achieved by a better acknowledgment of 
which method and intervention work best, and in what contexts. 
 
Interventions and methods for decreasing acquisition of HIV infection among MSM 
included HIV testing to detect and treat HIV positive persons and decrease the risk of 
HIV transmission which is known as TasP; community-level behavioral interventions 
to reduce high risk behaviors (1); condom use;  early detection and treatment of 
sexually transmitted Infections (STIs) (18); addiction and substance abuse 
counseling and mental health support when needed (19). Recently, the FDA had 
approved PrEP as a new biomedical intervention to be added to the list of prevention 
methods for HIV. The efficacy of PrEP has been proven in four randomized control 
trials and the efficacy is high when the drug is used as directed in the term of 
adherence for the treatment (20).  
 
PrEP implies the use of an antiretroviral drug to reduce acquiring HIV infection by 
uninfected people. This concept had been settled in the laboratories by animal 
studies and in real world application by post-exposure prophylaxis and the prevention 
of mother-to-child transmission (21). The safety of the two antiretroviral - FTC and 
TDF - being used for PrEP, has been proven through their use for treatment in HIV 
positive patients and in safety trials in uninfected people (22). Several clinical trials of 
effectiveness, Phase IIb and Phase III, had been organized in the last 10 years. 
These clinical trials focus on effectiveness of PrEP among high risk MSM, people 
who inject drugs, serodiscordant couples and heterosexual women (21). 
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The Epidemiology of HIV 
 
In 2013, there were 35 million patients living with HIV (23). Since the early beginning 
of the epidemic 78 million has become infected with the virus and 39 million have 
died of AIDS- related illness (23). Worldwide, 2.1 million individual became infected 
with HIV in 2013 and 1.5 million died from AIDS-related causes around 12.9 million 
people living with HIV had access to ARV therapy in the same year (23) (Table 1). 
On the regional level, the majority, 24.7 million, of people living with HIV are in sub-
Saharan Africa (table 2). 
 
Table 1: 2013 HIV Global Statistics 
 
Source: UNAIDS: Fact Sheet  2014 
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Table 2: 2013 HIV Regional and Global Statistics 
 
Source: UNAIDS: Fact Sheet  2014 
 
A global picture of HIV shows that the most common mode of transmission is through 
heterosexual intercourse (24). However, this picture differs in Europe. In most 
Europe, the HIV epidemic is highly concentrated in certain subpopulations including, 
MSM, people who inject drugs and migrants (specifically migrants from high HIV 
prevalence countries) (25-27). Available data shows that the prevalence of HIV 
among MSM is high and is continuing to increase in many countries throughout 
Europe (28). 
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In the West of Europe, there were 26 847 newly diagnosed cases with HIV infection 
in 2013 with a rate of 6.3 per 100 000 population (29). The most predominant mode 
of transmission was sex between men, followed by heterosexual sexual contact 
(Figure 1), accounting together for 77% of the new diagnosed cases (29). Sex 
between men accounted for 43% of the new diagnosed cases. Heterosexual contact 
accounted for 34% of the transmission. 4% of the acquired HIV infection were 
through injecting drug use and 0.7 % acquired through mother to child transmission 
(29). 
 
 
Figure 1: New HIV diagnosis, by transmission mode and year of diagnosis in West of Europe, 
2004-2013 
 
Source: European Centre for Disease Prevention and Control/ WHO Regional Office 
for Europe. HIV/AIDS surveillance in Europe 2013. Stockholm: European Centre for 
Disease Prevention and Control; 2014 
 
HIV prevalence among MSM in the 36 European countries that reported data, ranges 
from 0.5% to 17.7% (28). Prevalence is 5% or more in sixteen countries and 10% or 
more in 7 countries. The highest prevalence was reported by countries including 
France, Spain, Portugal, Belgium, Germany, Greece, Ireland, Italy and Switzerland 
(28).  
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The Concept of PrEP 
 
The concept of providing a preventive medication prior to exposure to a certain germ 
or virus is not a new concept and had been used to prevent other infections and 
diseases (30, 31). For instance, when individuals travel to a place where malaria is 
endemic, they should take malaria medication before and during travel to prevent 
getting infected in case bitten by a mosquito infected by malaria parasite (32-34). 
However, the use of antiretroviral medications to prevent HIV infection had only 
recently been approved (30, 31). When used consistently with adherence to 
treatment, PrEP has shown to decrease the risk of HIV infection among adults who 
are at high risk of acquiring the infection through sex, including heterosexually active 
men and women and MSM. Current evaluation of PrEP’s effectiveness in preventing 
HIV infection among people who inject drugs are underway, but those results are not 
yet available (30, 31). 
 
PrEP as a recent HIV prevention method in which people who are HIV negative take 
daily dose of antiretroviral to reduce their risk of acquiring the infection. The daily 
dose contains medications that prevent HIV from making new virus when it enters 
the body. TDF and FTC are phosphorylated intracellularly to form active agents that 
inhibit HIV replication (35).By this way PrEP medicines can help keep the virus from 
establishing a permanent infection inside the body(30, 31). 
 
TDF/FTC for PrEP must only be used by individuals who are HIV-negative and who 
continue to be HIV-negative during use for that they should be tested at least every 3 
months (35). PrEP is contraindicated in individuals with positive or unknown HIV 
status (30, 31) 
 
For individuals who are at high risk for sexual exposure to HIV, PrEP may be 
considered an important additional prevention method. PrEP is a comprehensive 
approach that requires strict adherence to medication and HIV testing. PrEP is not 
intended to be used as a sole intervention, but in combination with other HIV 
prevention methods such as counseling for sexual health reduction, repeated 
condom provision and early diagnosis and treatment of sexually transmitted infection 
(STI) (30, 31). In case PrEP is used effectively by individuals who are at high risk, it 
can play an important role in reducing the number of new HIV infections. 
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Clinical Trials  
 
Clinical trials of oral PrEP in different populations and settings started in 2005(34). 
Clinical trials of PrEP have been undertaken in more than 13 countries worldwide 
(Figure 2), including countries such as the US, Thailand, Peru, Ecuador, Brazil, 
Botswana, South Africa, Kenya, Uganda, Malawi, Tanzania, Zambia and 
Zimbabwe(36). The first generation of PrEP trials (Table 3) had enrolled more than 
20,000 study subjects and were designed to produce results in different populations 
groups, representing different routes of HIV transmission in Africa, the Americas, and 
Asia (35). They focused on either 300mg TDF or 300mg TDF/200mg FTC taken 
once daily (34). These studies are mainly sponsored by the US National Institutes of 
Health (NIH), the Bill & Melinda Gates Foundation (BMGF), the CDC, and the US 
Agency for International Development (USAID) (37). Gilead Sciences manufactures 
both TDF and TDF/FTC and affords the drugs for these trials (37). 
 
Figure 2: PrEP trials map worldwide - December 2009.  
 
Source: AIDS Vaccine Advocacy Coalition (AVAC) 
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Table 3: The First Generation of PrEP Clinical Trials 
 
Source: AVAC’s PrEP Trials Table 
 
Several PrEP studies have focused on MSM populations, for example: a study for 
testing the safety of daily oral TDF in US MSM; a study to determine the efficacy of 
oral daily Truvada® in MSM in Brazil, Peru, Ecuador, the US, South Africa, and 
Thailand; and a study of PrEP safety, acceptability and feasibility in young MSM (36). 
In addition, other PrEP trials established exploring the safety and efficacy of TDF-
based regimens in heterosexual men and women, heterosexual couples, and people 
who inject drugs. The chosen of TDF-based regimens based on the strength of pre-
clinical trials, in addition to the proven safety, tolerability, and resistance profiles of 
these medication when used as HIV treatment. All of these clinical trials are 
examining substantial safety data and tolerability in these different populations. 
Moreover, some of these went further to conduct sub-studies to test specific safety 
concerns that include evaluation of renal toxicity and examination of bone mineral 
density. All the clinical trials will assess pill-taking activities via participant self-report; 
another studies will assess pill-taking practices through objective measures such as 
microchips that can record the number of opening of pill bottles, counting returned 
pills and drug levels in plasma, blood cells, or hair. The clinical trials also assessed 
sexual and drug-use practices during the course of the trial. These clinical trials are 
also aimed to evaluate PrEP efficacy. The majority of these drugs are evaluating a 
single daily oral dose regimen, while the Partners in Prevention trial are evaluating 
both daily oral Truvada® versus TDF, and the VOICE trial are evaluating daily 
Truvada®, TDF and daily vaginal TDF. On the other hand, neither of these clinical 
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trials aimed for a direct comparison of different regimens, but both will present 
comparative efficacy data through the same trial. Finally, among MSM who become 
HIV positive while receiving PrEP, these clinical trials will provide data on patterns of 
HIV resistance, the impact on HIV viral load set point and CD4 cell count. Most of 
these studies are also evaluating sexual and drug-use practices through the course 
of the clinical trial. Concern has been increased that individuals may increase their 
risk practices if they have access to effective prevention methods. This alteration in 
risk behavior could be due to a decrease in self-imposed limits to avoid risk, which is 
known as behavioral disinhibition, or decreasing awareness of risk, known as risk 
compensation, with the obtainability of the new prevention method (38, 39). 
 
A website that contains updated data about the clinical PrEP trials is hosted by the 
AIDS Vaccine Advocacy Coalition: http://www.prepwatch.org. 
 
Clinical Trials Among MSM 
iPrEx 
 
The iPrEx trial was the first clinical trial to produce results (12). It was a phase III 
large-scale study conducted in six countries that include the US, Ecuador, Brazil, 
Peru Thailand and South Africa and aimed to test whether a daily combination of 
FTC and TDF could prevent HIV infection among MSM in an effective and safe way 
among sexually active gay men and transgendered women who have sex with men 
(21). Research participants were at least 18 years old and HIV-negative at the time 
of enrolment and had been assessed for HIV infection monthly for the duration of 
their participation in the study. The results of the study had been published in 
November 2010 and showed that there was a 44% (95% CI 15% - 63%) reduction in 
risk among PrEP recipients (12). The study included 2,499 MSM and transgender 
women who have sex with men, who were at high risk of HIV infection. Half of the 
participants were given once-daily oral FTC-TDF, Truvada®, and the other half of 
participants was given a placebo. All subjects received risk-reduction counseling and 
monthly HIV testing. Among those taking daily oral FTC-TDF, 36 became infected 
with HIV during the study, compared to 64 in the placebo group. The protective effect 
was higher among participants with good pill adherence. The side effects of the drug 
were mild and included a transient nausea, which disappeared after several weeks. 
In addition, some participants who took the active drug experienced a mild elevation 
of creatinine. These new findings from the iPrEX study pertain only to the 
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effectiveness of PrEP among MSM and cannot be extrapolated to other populations 
(40). 
 
After the release of the trial results the CDC issued a guidance for using PrEP for the 
prevention of HIV infection among MSM (41).  The guidance stated that for MSM at 
high risk for HIV infection, PrEP might represent an important additional prevention 
tool. PrEP in MSM should be used in combination with other HIV prevention methods 
and strategies and requires strict adherence (41). 
 
US MSM SAFETY TRIAL 
 
This trial was a phase II, randomized, placebo controlled, double blinded study of the 
behavioral effects and clinical safety of TDF as a PrEP among four hundred MSM 
participants (42). The study took place in 3 cities in the US that include Atlanta, 
Boston and San Francisco (43) had been sponsored by the CDC. The study subjects 
were assigned randomly 1:1:1:1 to receive a daily oral dose of TDF or placebo 
immediately or after nine month delay(42). Participants were assigned for follow-up 
visits one month after enrollment and 4 months after that. Medication adherence was 
high among participants without direct medication interruption (the adherence was up 
to 92% using pill count and up to 77% using pill bottle openings recorded by 
Medication Event Monitoring System caps (42). After running a multivariable 
analysis, the only adverse effect that was associated with TDF was back pain. In a 
portion of participants at the San Francisco (n=184) for whom bone mineral density 
(BMD) had been assessed, the receipt of TDF was found to be associated with small 
decrease in BMD (0.8% decrease for total hip and 1% decrease at the femoral neck) 
(44), but at the same time, the reception of TDF was not associated with bone 
fractures at any anatomical site. No HIV with mutations accompanied by TDF 
resistance was recorded among seven seroconversions (43). In addition, among 
participants who were given TDF, no HIV infections occurred; 3 seroconversions 
occurred in men while taking placebo, another 3 seroconversions occurred among 
men who were in the delayed TDF group but had not started receiving drug and one 
seroconversion occurred in a man who had been assigned randomly to receive 
placebo and was later on discovered to have had acute HIV infection at the 
enrollment visit (43). 
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This study evaluated the possibility for an alteration in sexual risk practices via its 
unique study scheme, which randomized half of the participants to take a daily pill of 
TDF or placebo upon enrollment, while the other half are randomly allocated to wait 
nine months prior to starting their daily study pill (Figure 3). This permits a direct 
comparison of risk behaviors and practices while men are or are not taking a daily 
pill, and may provide an early indication if there is likely to be significant risk 
compensation. 
 
Figure 3: Study design of US CDC tenofovir (TDF) study  
 
Source: Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of 
combination prevention approaches. AIDS and behavior. 2011;15(1):72-9. 
 
The PROUD study 
The PROUD study took place in the UK and randomized participants to either 
immediate or deferred PrEP (after one year) using daily Truvada®. The data safety 
monitoring board recommended, on October 16 2014, to give daily PrEP to all trial 
participants because PrEP was highly protective against HIV (45). 
 
 The IPERGAY study 
The IPERGAY study took place at six hospitals in France and one in Canada. It was 
used "on demand" prophylaxis only at the time sexual intercourse. A significant 
difference in incidence of HIV infection in the on demand PrEP group was found, and 
"on demand" Truvada® recommended to all trial participants (47). 
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Rationale for HIV Prophylaxis Using Antiretroviral Agents 
 
Current efforts to prevent, control and treat HIV are starting to yield results. 
Noteworthy extension of antiretroviral therapy had led to reduced mortality. There 
had been some steadiness or decline in new HIV infections through several countries 
in sub-Saharan Africa, which is home of 67% of all individuals living with HIV(46). 
Data indicate that there were 400,000 less new infections in that area in 2008 than 
there were in 2001 (47). Although these promising progresses, much effort remains. 
Generally, HIV prevalence is disappointingly high and continues to rise in several 
parts of the world. HIV excessively affects MSM, PWID and sex workers (46). 
Despite that behavioral interventions are essential, and structural plans are needed 
to address the underlying factors of vulnerability to HIV, technology can also provide 
a much needed addition to the prevention methods. Developments in understanding 
of the pathogenesis of HIV have headed to more complex research on prevention 
strategies (37). Studies have revealed that early in infection, HIV targets and 
destroys cells of the immune system that are probably adapted to prevent 
establishing and control development of disease (48) .It is thus significant to 
intervene before infection is established and track all opportunities to develop a well-
planned set of combination prevention. This set must contain effective and 
complementary modalities to reduce rates of HIV transmission to the highest degree 
possible (49, 50). One technological prevention choice that could be of great value is 
PrEP, which is an approach for HIV-negative individuals to decrease their risk of 
acquiring the infection by taking oral antiretroviral drugs used for HIV treatment.  
 
As discussed earlier, this approach had been evaluated in a number of studies in 
different populations worldwide, but ‘‘Can a pill a day prevent HIV?’’ this was the 
tagline of recruitment campaign for HIV prevention trial to test whether a combination 
pill of TDF and FTC could reduce the number of HIV infections when taken daily 
among MSM (36). The general principle underlying PrEP is clear: medications that 
are offered as treatment can be used to prevent infection among persons highly 
exposed for HIV or those who are more susceptible to the infection, and as any 
infectious disease that can’t be controlled by antimicrobials alone, the control of HIV 
will be achieved through a combination of behavioral and biomedical methods and 
interventions (51). Even in chronic diseases such as coronary heart disease, 50 % 
decline in mortality was achieved in the US from 1980 to 2000 through a combination 
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of strategies that include modification of risk factors and biomedical interventions 
(52). Chloroquine was used to treat malaria and also to prevent it among individuals 
travelling to malarias districts (37). Another example is isoniazid, which is still used 
as prophylaxis in high-risk sets and as part of the treatment routine for tuberculosis. 
Observing the current epidemiology of the HIV epidemic, PrEP may be suitable 
targeted prevention strategy. Numerous accomplished pre-clinical studies in diverse 
animal models have shown promise. Macaques animals treated daily with FTC were 
less likely to be infected after rectal exposure to a simian version of HIV (SHIV) than 
untreated Macaques. Animals treated with oral FTC and TDF at similar doses to a 
human corresponding dose had an even lesser rate of seroconversion (37). 
Moreover, macaques treated daily with two antiretroviral drugs, FTC and TDF, at 
high doses were totally protected from HIV infection (53). HIV negative adults at high 
risk receive antiretroviral products formulated as pills or gels that prevent HIV 
replication during periods of HIV exposure as prophylaxis versus infection (54, 55). 
 
At population level, combination of different interventions that target different 
mechanisms of the HIV epidemic could be synergistic at a population level (56). For 
instance, in South Africa, a model that was testing the impact of combining male 
circumcision with a behavior change program found that male circumcision alone 
with 90% coverage would lead to one-third reduction in the incidence of HIV at 
population level. On the other hand, a behavior change program alone with 30% 
increase in condom use and 30% reduction in the rate of partner change would result 
to 2/3 reductions in HIV incidence rates. Nonetheless, in case we combined male 
circumcision with a behavior change program, HIV incidence would be nearly 
eliminated (57), and because PrEP is not 100% effective, therefore it needs to be 
combined with the other HIV prevention interventions to have the greatest impact.  
 
Disease burden of HIV in MSM 
 
Since the early beginning of HIV epidemic in the early 80s, MSM were one of the 
main populations affected by the disease (58, 59). Although there was important 
advanced and societal progress in the field of treatment, prevention and support in 
the past 3 decades, the epidemics of STIs and HIV in MSM are expanding 
worldwide, even in several countries with generalized HIV epidemics (60), because 
the effectiveness of this measures is dramatically affected by social and structural 
factors in the MSM groups (61). In addition, MSM face some political and structural 
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barriers to accessing services in many settings owing to their marginalized and 
stigmatized status (21). The substantial burden of HIV in MSM suggests that 
currently existing methods of HIV prevention are not sufficient and additional 
prevention methods should be considered (21). Worldwide, the odds of being 
infected with HIV are 19.3 times higher in MSM than for men in the general 
population (60). In many countries around the world, while there was an observed 
decline in HIV incidence, a steady increase in the number of new cases in MSM has 
been reported and documented (Figure 4) (62).  
 
Figure 4: Global prevalence of HIV in MSM compared with regional adult prevalence reported by 
UNAIDS, 2010. 
 
Source: McKeown E, Doerner R, Nelson S, Low N, Robinson A, Anderson J, et al. 
The experiences of ethnic minority MSM using NHS sexual health clinics in Britain. 
Sexually transmitted infections. 2012;88(8):595-600. 
 
In the European Union, the largest increase in new infections was reported in MSM 
(64) (Figure 5). In several high-income countries like France, UK, USA and Australia, 
the overall epidemic trends are declining except in MSM (65, 66). There is a defect in 
understanding the worldwide epidemic. Total of 93 country from 196 had not 
provided any reports about the prevalence of HIV in MSM in the last 5 years by the 
end of the year 2011 (67). There are gaps in the data of the epidemiological 
characterization of the HIV infection in MSM, obstacles toward establishing 
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successful HIV research and surveillance because of the stigmatized and hidden 
nature of the MSM population in several countries, and of the continuous 
criminalization of same sex acts (67). 
 
Figure 5: HIV prevalence among MSM in Europe and Central Asia 
 
Source: European Centre for Disease Prevention and Control. Thematic 
report: Men who have sex with men. Monitoring implementation of the Dublin 
Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 
2012 Progress Report. Stockholm: ECDC; 2013. 
Migrants and HIV 
 
Migration and mobility are main factors that affect a wide range of social outcomes 
and results (63). Migration plays a vital role as a key factor for HIV transmission 
worldwide (64, 65). Migration to Europe had risen dramatically in the past few 
decades, with a great burden and implications for public health services (66). With an 
estimation of about 72.6 million migrants now living in Europe, the region is an 
increasingly attracting one third of the world migrant population (67, 68). Infectious 
diseases are determined to be the main health issue for new migrants from middle 
and low income countries, with asylum seekers and refugees considered to be 
particularly affected (69). Multiple factors contribute to the vulnerability of new 
migrants to infectious diseases, with migrants known to face several barriers to 
healthcare, which may result in postponement to screening, diagnosis and treatment 
(70). Migrants may be affected concerning their ability to access and benefit from 
screening programs for infectious disease as they attempt to navigate a new health 
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system (71). In addition, they face individual, economic, socio-cultural, political and 
administrative barriers when using health services (66). Evidences from several 
studies suggest that epidemics of STIs are underway among MSM in developing 
countries (72). Developing countries are the main source of migrants worldwide (72, 
73). Available data about MSM in Africa, Asia, south and central America, the former 
Soviet Union and the Caribbean are remarkably showing that MSM are at substantial 
risk for STIs (72). 
 
Some of the migrant populations are highly expressed in the new cases of HIV in 
Europe (74), particularly in western countries.  Migration plays a vital role as a key 
factor for HIV transmission worldwide (64, 65). An additional aggravating factor is the 
observation that migrants face individual, economic, socio-cultural, political and 
administrative barriers when using health services (66). 
 
Although the epidemics of HIV in migrants in Europe is more visibly linked to 
heterosexual transmission, also migrant MSM from countries with generalized 
epidemics may be at higher risk of acquiring and transmit HIV post migration, a 
subject which has been comparatively neglected (75). Several factors such as the 
stigma associated with homosexuality in the country of origin, may interfere with 
knowledge about sexual health as well as with preventive behaviors of migrant MSM 
(75, 76). 
 
Evidence accumulated thus far shows that in the US migrant MSM are at high risk for 
several poor health outcomes such as HIV and STI (77). MSM ethnic minorities in 
the US, especially African Americans and Latino, have the highest rates of new AIDS 
cases and STIs (77). Accordingly, a British study among MSM found that black men 
are 2.06 times as likely to be living with HIV infection in comparison to the white 
British majority, while Asian men are 0.32 times as likely to be infected (78). Another 
British study that aimed to examine rates of STIs and sexual behavior in black and 
minority ethnic including Caribbean, African or other MSM, showed that black and 
minority ethnic MSM were significantly more likely to report unprotected anal 
intercourse in the preceding three months, when white British were used as a 
comparison group (79). 
 
Different cultures and the constrains of adapting to the country of residence can 
contribute to migrant MSM acquiring higher risk behavior (80). The EMIS study report 
showed that in general, migrant status was associated with some risk behavior that 
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may place migrants at higher risk of acquiring HIV (80). In addition, a greater 
prevalence of history of STIs or HIV infection with lower level of access to affordable 
HIV and STI testing was found among migrant participants (80).  
 
Portugal has historically been a country of emigration and important immigration 
flows started much more recently (81). The country witnessed high inflow of Brazilian 
migrants, migrants from the African Portuguese-speaking countries, in addition to the 
labor migrants from Eastern Europe (82). In 2013, foreign population with regular 
residence as a percent of the resident population formed 3.8% of the total population 
(83).  
 
HIV and MSM in Portugal 
 
In Portugal, although the considerable health improvements in recent decades (84) 
and despite adopting many measures to improve the performance of the Portuguese 
healthcare system, including the reorganization of primary care and setting a long-
term care networks (84), HIV infection continues to be of major public health 
importance in the country(85). MSM are substantially at high risk of being affected by 
the HIV epidemic (86). In Portugal, and according to national HIV prevalence data, 
the prevalence of HIV in men who have sex with men is 11% (15). In 2013, 4 369 
cases of AIDS were diagnosed and reported by 29 EU/EEA countries, with a rate of 
0.9 cases / 100 000 population. The highest rates were diagnosed and reported by 
Latvia (6.6) and then by Portugal (3.1) (29). In Portugal, as a part of West of Europe, 
the HIV epidemic is highly concentrated in three sub-groups: MSM, PWID and 
migrants (specifically migrants from high HIV prevalence countries) (6-8). The 
prevalence of HIV among adults can reach up to 0.9 % (87). 
 
Portuguese official surveillance data showed an annual 9% increase in the number of 
newly diagnosed cases of HIV among MSM from 2005 to 2102, while there was a 
decrease by 2% in the new cases due to heterosexual intercourse and decrease by 
18% in new cases due to unsafe injection behavior (85, 88). The proportion of MSM 
among all HIV cases diagnosed in 2013 amounted to 42.9 % while MSM represent 
approximately 3% of the male adult population (85, 88). This means that existing 
approaches to prevention have failed to control the HIV epidemic among MSM in 
Portugal; accordingly PrEP can be an additional new effective intervention against 
HIV infection in MSM that can control and curb the infection among MSM in Portugal. 
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The CDC Eligibility Criteria 
 
Several organizations and Institutes such as CDC (30, 31), The New York State 
Department of Health AIDS Institute (NYSDOH AI) (89) and the World Health 
Organization (WHO) (90, 91) set certain guidelines and criteria to assist practitioners 
in assessing eligibility for PrEP, especially in key population such as serodiscordant 
couples, MSM and people who inject drugs (30, 31, 89-91).  These guidelines are 
based on the results of the clinical trials, as well as on the review of published data 
(30, 31, 89-91). Our study estimated the Eligibility for PrEP using the criteria of the 
CDC, which follows the U.S. Public Health Service. IN 2014, the U.S. Public Health 
Service has published a comprehensive clinical practice guideline for the use of 
PrEP for the prevention of HIV infection in the US (92). The eligibility criteria for PrEP 
included; Unprotected anal intercourse, High number of sex partners, Sero-
discordant sexual relationship with a known HIV-infected partner, Transactional sex 
and Recent bacterial STI (92). 
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OBJETIVES 
 
• We aimed to estimate the proportion of MSM eligible for PrEP participating in 
the European MSM Internet Survey (EMIS) among: 1) Portuguese-born living 
in Portugal, 2) non-Portuguese-born living in Portugal, and 3) Portuguese-
born living abroad.  
 
• To identify predictors of eligibility among the 3 groups. 
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ELIGIBILITY FOR HIV PREP AMONG MEN WHO HAVE SEX WITH MEN: 
PORTUGUESE, PORTUGUESE MIGRANTS AND MIGRANTS IN PORTUGAL 
 
A NABIL, A MARTINS, P MEIRELES, R LUCAS, R FUERTES, MJ CAMPOS, L 
MENDÃO, H BARROS 
 
EPIUNIT – Institute of Public Health, University of Porto, Porto, Portugal  
Departamento de Epidemiologia Clínica, Medicina Preditiva e Saúde Pública, 
Faculdade Medicina da Universidade do Porto, Instituto de Saúde Pública da 
Universidade do Porto, Porto, Portugal 
Grupo Português de Activistas sobre Tratamentos VIH/SIDA (GAT), Lisboa, 
Portugal. 
 
Background: 
 
HIV pre-exposure prophylaxis (PrEP) comprises the use of antiretroviral medications 
by HIV negative individuals to decrease infection risk. Men who have sex with men 
(MSM) have higher rates of HIV infection. Among migrants MSM, certain types of 
cultures, stigma, and barriers to seek medical advice, may increase the risk of 
acquiring the infection. 
 
Objectives: 
 
We aimed to estimate the proportion of MSM eligible for PrEP participating in the 
European MSM Internet Survey (EMIS) among: 1) Portuguese-born living in 
Portugal, 2) non-Portuguese-born living in Portugal, and 3) Portuguese-born living 
abroad, and to identify the predictors of eligibility. 
 
Method: 
 
Data were obtained through EMIS, a cross sectional study that took place from June 
to August 2010. An anonymous questionnaire was completed online (38 European 
countries using 25 languages) by 184 469 participants, of which 5187 lived in 
Portugal (80.7% Portuguese-born and 17.4% migrants) and 375 Portuguese-born 
lived abroad. Migrants were defined as men who were born in other country than 
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their current country of residence, while expatriates defined as men born in one of 
the 38 EMIS countries but currently living in one of the other 37 EMIS countries. The 
proportion of expatriates for a country is the number of men born there but not living 
there, compared to the total number of men born in the country. Information on HIV 
status, socio-demographic and behavioral characteristics was collected. Eligibility for 
PrEP was estimated according to the guidelines of the Centers for Disease Control 
and Prevention.  Proportions were compared using the Chi-squared test and Odds 
Ratios (OR) with 95% confidence interval (95% CI) were computed using logistic 
regression. 
 
Results: 
 
Similar proportions of MSM eligible for PrEP were found among migrants living in 
Portugal (46.3%), Portuguese-born living in Portugal (44.4%) and Portuguese-born 
living abroad (45.1%) (p=0.621). In migrants living in Portugal, participants from Latin 
America and Caribbean region origin were more likely to be eligible for PrEP in 
comparison to Portuguese-born (OR=1.27; 95%CI 1.04-1.58; p=0.023). Portuguese-
born living in Portugal showed the highest number of predictors for PrEP in 
comparison to the other 2 groups. In Portuguese-born living in Portugal, individuals 
who had ever undergone post-exposure prophylaxis were more likely to be eligible 
for PrEP (OR=2.26; 95% CI 1.30-3.93; p=0.004). In the same category having HIV 
test result in the last 12 months, having sex abroad with a man who was not from 
country of residence, consumption of any reactional drugs in the last 12 month or 
ever been tested for STIs other than HIV, increase the odds of being eligible for 
PrEP. Among migrants living in Portugal Migrants who reported having sex abroad 
with a man who was not from the country of residence in the previous 12 months 
were more likely to be eligible (OR=1.72; 95%CI 1.22-2.41; p=0.002). Migrant MSM 
who visited a social commercial venue in their country of residence were more 
eligible for PrEP in comparison to those who never sex venues (OR= 2.14; 95% CI 
1.36-3.38; p=0.001). In Portuguese living abroad, individuals whose level of 
education was middle were more eligible for PrEP (OR= 1.74; 95% CI 1.06-2.86; 
p=0.029). Participants who received HIV test results in the last 12 months were more 
frequently eligible for PrEP in comparison to participates who didn’t receive HIV 
results (OR= 1.84; 95%CI 1.17-2.90; p= 0.007).  
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Introduction: 
 
Evidence from large-scale observational research and clinical trials conducted 
among multiple high-risk populations has demonstrated that Antiretrovirals (ARVs) 
can be used effectively as a PrEP to reduce the risk of acquiring HIV infection (1). In 
July 2012, on the basis of the results of these clinical trials, the U.S. Food and Drug 
Administration (FDA) approved the use of a combination of tenofovir + emtricitabine 
(TDF/FC) as pre-exposure prophylaxis to reduce the risk of HIV in adults at high 
risk(2).  
 
The Centers for Disease Control and Prevention (CDC) (3, 4), The New York State 
Department of Health AIDS Institute (NYSDOH AI) (5) and the World Health 
Organization (WHO) (6, 7) set certain guidelines and criteria to assist practitioners in 
assessing eligibility for PrEP, especially in key population such as serodiscordant 
couples, MSM and people who inject drugs (3-7).  These Guidelines are based on 
the results of the clinical trials, as well as on the review of published data (3-7). 
 
In most Europe, the HIV epidemic is highly concentrated in certain subpopulations 
including men who have sex with men, people who inject drugs and migrants 
(specifically migrants from high HIV prevalence countries) (8-10). Available data 
show that the prevalence of HIV among MSM is high and is continuing to increase in 
many countries throughout Europe (11). In West of Europe, there were 26 847 newly 
diagnosed case with HIV infection in 2013 with a rate of 6.3 per 100 000 population 
(12). The most predominant mode of transmission was sex between men, followed 
by heterosexual sexual contact, accounting together for 77% of the new diagnosed 
cases (12). Sex between men accounted for 43% of the new diagnosed cases. 
Heterosexual contact accounted for 34% of the transmission. Four percent of the 
acquired HIV infection were through injecting drug use and 0.7 % acquired through 
mother to child transmission (12). 
 
HIV prevalence among men who have sex with men (MSM) differs across Europe 
but is considered high in many western and southern European countries: in the 36 
European countries that reported data, prevalence estimates range from 0.5% to 
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17.7% (11). Prevalence is 5% or more in sixteen countries and 10% or more in 7 
countries. The highest frequency was reported by countries including France, Spain, 
Portugal, Belgium, Germany, Greece, Ireland, Italy and Switzerland (11). In Portugal, 
men who have sex with men are at high risk of being affected by the HIV epidemic 
(13) and, using self-reported information on serological status, the prevalence of HIV 
in men who have sex with men was estimated at 11%(14). 
 
Some of the Migrant populations are highly expressed in the new cases of HIV in 
Europe (15), particularly in western countries.  Migration plays a vital role as a key 
factor for HIV transmission worldwide (16, 17). An additional aggravating factor is the 
observation that migrants face individual, economic, socio-cultural, political and 
administrative barriers when using health services (18). 
 
Although that the epidemics of HIV in migrants in Europe is more visibly linked to 
heterosexual transmission, also migrant men who have sex with men from countries 
with generalized epidemics may be at higher risk of acquiring and transmit HIV post 
migration, a subject which has been comparatively neglected (19). Several factors 
such as the stigma associated with homosexuality in the country of origin, may 
interfere with knowledge about sexual health as well as with preventive behaviors of 
migrant MSM (19, 20). 
 
Evidence accumulated thus far shows that in the US of America migrant MSM are at 
high risk for several poor health outcomes such as HIV and STI (21). MSM ethnic 
minorities in the US, especially African Americans and Latino, have the highest rates 
of new AIDS cases and STIs (21). Accordingly, a British study among MSM found 
that black men are 2.06 times as likely to be living with HIV infection in comparison to 
the white British majority, while Asian men are 0.32 times as likely to be infected 
(22). Another British study that aimed to examine rates of STIs and sexual behavior 
in black and minority ethnic including Caribbean, African or other men who have sex 
with men (MSM), showed that black and minority ethnic MSM were significantly more 
likely to report unprotected anal intercourse in the preceding three months, when 
white British were used as a comparison group (23). 
 
Portugal has historically been a country of emigration and important immigration 
flows started much more recently (24). The country witnessed high inflow of Brazilian 
migrants, migrants from the African Portuguese-speaking countries, in addition to the 
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labour migrants from Eastern Europe (25). In 2013, foreign-born population with 
regular residence in the country formed 3.8% of the total resident population(26).  
 
 In comparison to the current prevention methods such as voluntary counseling, 
testing, condom use and lubricants, PrEP is an additional effective intervention, 
which had shown efficacy against HIV infection in MSM. Therefore detecting the 
prevalence and predictors of eligibility for HIV PrEP in the Portuguese sample of the 
European Men Who Have Sex with Men Internet Survey (EMIS), the largest sample 
of MSM ever studied in Portugal, will help to better understanding of the magnitude 
of the problem prior to its adoption as a new effective HIV preventive method in 
Portugal. We aimed to estimate the proportion of MSM eligible for PrEP participating 
in the European MSM Internet Survey (EMIS) among: 1) Portuguese-born living in 
Portugal, 2) non-Portuguese-born living in Portugal, and 3) Portuguese-born living 
abroad, and to identify the predictors of eligibility. The study’s significance lies in 
adding to efforts in controlling and withholding the spread and the rise in HIV 
infections at one of most at high-risk population as well as knowing the determinants 
of a new prevention method as PrEP in Portugal. 
 
Methods: 
 
The EMIS Study 
 
The EMIS is a multilingual Internet-based survey for MSM and living in Europe (27). 
The study included 184466 participants. MSM across 38 European countries, 
including the 27 EU Member countries, filled in an online questionnaire on their 
several domains of their sexual health, which was made available in 25 different 
languages.  
 
The survey had been developed through collaboration between 5 primary and 77 
secondary partners working in MSM sexual health through public health, academic 
and community organizations in Europe (27-29). The recruitment method and data 
collection had been designed to attract a large sample of MSM in Europe and was 
promoted through a wide variety of 235 trans-national websites for MSM, 
nongovernmental organizations and gay online social media that include Gaydar, 
PlanetRomeo, Manhunt and other gay community organizations(27).  
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Individuals who confirmed that they had read and understood the goal of the 
study and were legally of age to have consensual sex with men in their country 
of residence were directed to the survey questions. Upon choice of the language, 
the study website explained the research in the chosen language. Men who 
confirmed they had read and understood the purpose of the study and were lawfully 
of age to have sex with men in their country of residence were directed to the survey 
questions (28). The survey questions were the outcome of more than a year’s effort 
of investigating scientific literature, agreed indicators, consulting a large number of 
NGOs and exploring preceding questionnaires (30). The study was initially 
conducted for comprehension and length by MSM in 21 collaborating countries (29). 
This was an extensive procedure because EMIS needed questions, which were 
appropriate for the whole European MSM population irrespective of their sexual 
identity, or the social and political background in which they existed. The final form of 
self-completion survey comprised of about 280 questions, but was customized using 
intra-survey filters, which based on the respondent’s answer to preceding questions 
(28). Guidelines for answering the survey and descriptions of terms were offered 
within the survey. Slang language had been used because it is supposed to increase 
reporting of socially unwanted behavior (31). The median accomplishment time was 
about 20 min, which was calculated from the accurate completion time for each 
survey, which was auto-captured as an integral segment of the survey software used 
(28, 29). The survey software installed no cookies or left any other trace files on 
computers, and no IP-addresses were saved or no other data that could be used to 
recognize computers and hence participants (28). This guaranteed that survey was 
completely anonymous. The respondent had to accomplish the survey in one sitting. 
The answers were only recorded by the respondent ticking through to the final page 
and selecting the submit button. The survey was accessible for online completion 
within 12 weeks in June through August 2010, and all processes were approved by 
the Research Ethics Committee of the University of Portsmouth, United Kingdom 
(27). For further information about the EMIS survey and methodology the following 
sources are recommended www.EMIS-project.eu and the EMIS final report (27). 
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Participants 
 
For this study, we examined several sociodemographic, behavioral characteristics 
and testing behaviors measured in EMIS. The outcome of interest, eligibility for HIV 
PrEP, was measured within the three-group categories: 1) Portuguese-born living in 
Portugal, 2) non-Portuguese-born living in Portugal, and 3) Portuguese-born living 
abroad. The sample included 5187 participant lived in Portugal (80.7% Portuguese-
born and 17.4% migrants) and 375 Portuguese-born lived abroad (representing 8.1% 
of Portuguese-born and now living in other EMIS countries). 
 
Migrants 
 
In the EMIS survey, migrants were defined as men who were born in another country 
than their current country of residence (27). Based on this definition, through Europe, 
11.9% of respondents were migrants. The highest proportion of migrants was 
recorded in Luxembourg (50%) and the highest proportion of migrants by sub-region 
was in West of Europe (22%). The proportion of migrants in Portugal was 17.4% 
(27). In most sub-regions, the largest proportion of migrants came from the same 
sub-region, nevertheless in Southwest the largest proportion of migrants was from 
Latin America (27).  
  
Expatriates  
 
EMIS defined expatriates as men born in one of the 38 EMIS countries but currently 
living in one of the other 37 EMIS countries (27). The proportion of expatriates for a 
country is the number of men born there but not living there, compared to the total 
number of men born in the country which is an another way of looking at migration by 
considering the country of birth, rather than taking the perception of the current 
country of residence, and observing at the percentage of people born abroad (27). 
The EMIS stated that these figures should be treated with carefulness, because they 
eliminate men born in EMIS countries but now living outside those countries (27). 
Germany had the lowermost proportion of expatriates: only 4% of all EMIS 
respondents born in Germany were living in one of the other 37 EMIS countries, the 
highest proportions of expatriates were recorded in Bosnia and Herzegovina (56%) 
and Cyprus (34%), while it was (8.1%) in Portugal which also shows the countries 
with the percentages of expatriates distributed across the sub-regions.  
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Statistical analysis 
 
Eligibility for PrEP was estimated according to the guidelines of the CDC that 
includes individuals with HIV-positive sexual partner, recent bacterial STI, high 
number of sex partners and Transactional Sex (3-5). The individuals are considered 
clinically eligible if they are HIV negative and so exclusion of HIV positive cases had 
been made. According to these criteria a list of variables, which have been used in 
the EMIS Portuguese sample, were selected after matching it with the previous CDC 
criteria (3-5). Proportions of eligibility for HIV PrEP in the 3 groups categories were 
compared using the Chi-squared test and odds Ratios (OR) with 95% confidence 
interval (95% CI) were computed using logistic regression to determine the indicators 
for PrEP. These indicators included several characteristics such as HIV and STIs 
testing behaviors, consumption of drugs, attendance of sex venues, exposure to post 
exposure prophylaxis and having sex abroad. 
 
Results: 
Stratifying the eligibility for PrEP according to the CDC’s eligibility criteria (table1) 
show that Non-monogamous relations with unprotected anal intercourse (UAI) in the 
last 6 months accounts for 96.2% of the eligibility for PrEP in Portuguese-born living 
in Portugal, 93.3% in non-Portuguese-born living in Portugal, and 93.0% of the 
Portuguese-born living abroad.  
 
Similar proportions of MSM eligible for PrEP (table 2) were found among migrants 
living in Portugal (46.3%), Portuguese-born living in Portugal (44.4%) and 
Portuguese-born living abroad (45.1%) (P=0.621), but after classifying migrants living 
in Portugal according to region of origin (table 3), we found that participants from 
Latin America and Caribbean were more likely to be eligible for PrEP in comparison 
to Portuguese-born (OR=1.27; 95%CI 1.04-1.58; p=0.023) and among migrants who 
were eligible for PrEP 38.6% were from Latin America and Caribbean region. 
 
In Portuguese-born living in Portugal (table4), being Ever tested for STIs other than 
HIV was associated with increase the eligibility for PrEP (OR= 1.35; 95% CI 1.17-
1.54; p<0.001). Individuals who had ever undergone post-exposure prophylaxis were 
more likely to be eligible for PrEP (OR=2.26; 95% CI1.30-3.93; p=0.004). In the 
same category, participates who identified themselves as homosexuals were more 
like to be eligible for PrEP in comparison to individuals who identified themselves as 
bisexual or other, (OR= 1.46; 95%CI 1.26-1.69; p= <0.001). In addition, having HIV 
 40 
test result in the last 12 months, having sex abroad with a man who was not from 
country of residence or the consumption of any reactional drugs in the last 12 month 
increase the odds of being eligible for PrEP. In migrants living in Portugal, 
participants from Latin America and Caribbean were more likely to be eligible for 
PrEP in comparison to Portuguese-born (OR=1.27; 95%CI 1.04-1.58; p=0.023). 
Among migrants who were eligible for PrEP (n=359) (table 5), 71.2% identified 
themselves as homosexuals, 57.5% of high educational level and 74.1% were 
employed. Migrants who reported having sex abroad with a man who was not from 
the country of residence in the previous 12 month were more likely to be eligible 
(OR=1.72; 95%CI 1.22-2.41; p= 0.002). Migrant MSM who visited a social 
commercial venue in their country of residence were more eligible for PrEP in 
comparison to those who never sex venues (OR= 2.14; 95% CI 1.36-3.38; p=0.001). 
In Portuguese-born living abroad (table4), individuals whose level of education were 
middle were more frequently eligible for PrEP (OR= 1.74; 95% CI 1.06-2.86 
P=0.029). In the same category, 62.2% of participants who received HIV results in 
the last 12 month were eligible for PrEP. Participants who received HIV test results in 
the last 12 months, after exclusion of HIV positive cases, were more frequently 
eligible for PrEP in comparison to participates who didn’t receive HIV results (OR= 
1.84; 95%CI 1.17-2.90; p= 0.007).  
 
Table1: Eligibility criteria for HIV PrEP among MSM in Portugal according to place of birth and migration 
status after exclusion of HIV positive cases. 
 CDC Eligibility Criteria for PrEP Total n (%) 
 Non-
monogamous w 
HIVneg and UAI 
last 6 months 
n(%) 
Non-
monogamous w 
HIVneg. and 
diagnosed with 
an STI last 6 
months n (%) 
Steady partner 
with HIV n (%) 
 
Portuguese-born 
living in Portugal 
1562 (96.2) 20 (1.2) 42 (2.6) 1624 (100) 
Non-
Portuguese-born 
living in Portugal 
(Migrant) 
335 (93.3) 12 (3.3) 12 3.3 359 (100) 
Portuguese-born 
living abroad 
133 (93.0) 5 (3.5) 5 (3.5) 143 (100) 
Total 2030 (95.5) 37 (1.7) 59 (2.8) 2126 (100) 
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Table 2 Eligibility for HIV PrEP among MSM in Portugal according to place of birth and migration status 
after exclusion of HIV positive cases. 
 
Table 3 Eligibility for HIV PrEP after classifying Migrants according to their region of origin. 
 
 
 
  CDC Eligibility criteria for PrEP  
 Eligible n (%) Not Eligible n (%) OR (95% CI) P-value 
Portuguese-born living in Portugal 1624 (44.4) 2032 (55.6) 1  
Non-Portuguese-born living in Portugal (Migrant) 359 (46.3) 416 (53.7) 1.080 (0.92-1.26) 0.333 
Portuguese-born living abroad 143 (45.1) 174 (54.9) 1.028(0.81-1.29) 0.812 
Total 2126(44.8) 2622 (55.2)   
 CDC Eligibility for PrEP 
 Not Eligible n(%) Eligible n(%) OR (95% CI) P-value 
Country/Region of 
origin (regionorigin) 
 
Born in Portugal 2032 (77.5) 1624 (76.4) 1  
West Europe 55 (2.1) 46 (2.2) 1.04(0.70-1.55) 0.823 
Northwest   Europe 3 (0.1) 1 (0.0) 0.41(0.43-4.01) 0.449 
Central-west Europe 25 (1.0) 14 (0.7) 0.70(0.363-1.35) 0.289 
Southwest Europe 197 (7.5) 152 (7.1) 0.96(0.77-1.35) 0.755 
Central-East Europe 4 (0.2) 3 (0.1) 0.93(0.21-4.19) 0.934 
Southeast (EU) 
Europe 
5 (0.2) 0(0.0) 0.00 0.999 
Southeast (non-EU) 
Europe 
1(0.0) 0(0.0) 0.00 1 
East Europe 5(0.2) 4(0.2) 1.00(0.26-3.73) 0.999 
WHO Region of the 
Americas: Canada, 
USA 
12(0.5) 8(0.4) 0.83(0.34-2.04) 0.692 
WHO Region of The 
Americas: Latin 
America and 
Caribbean 
190(7.2) 194(9.1) 1.27(1.03-1.57) 0.023 
WHO Eastern 
Mediterranean Region 
1(0.0) 0(0.0) 0.00 1 
WHO African Region 88(3.4) 76(3.6) 1.08(0.79-1.47) 0.628 
WHO Western Pacific 
Region: Australia and 
New Zealand 
2(0.1) 1(0.0) 0.62(0.05-6.90) 0.702 
WHO Western Pacific 
Region: (excl. 
Australia and New 
Zealand) 
2(0.1) 3(0.1) 1.87(0.31-11.24) 0.491 
Total 2622(100) 2126 (100)   
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Table 4: Predictors for the eligibility for HIV PrEP according to participants’ characteristics, results from 
EMIS 2010 
Predictors for the eligibility for HIV PrEP in Portuguese-born living in Portugal according to participants’ 
characteristics, results from EMIS 2010 
 Not Eligible n 
(%) 
Eligible 
n (%) 
 OR (95% CI) P-
value 
Age      
<25 604 (29.7) 453 (27.9) 1  
25-39 1054 (51.9) 848 (52.2) 1.07 (0.92-
1.24) 
0.364 
>or =40 374(18.4) 323 (19.9) 1.15 (0.95-
1.39) 
0.151 
Sexual Identity      
Bisexual/other 687(33.9) 419 (25.9) 1  
Homosexual 1342(66.1) 1198 
(74.1) 
1.46(1.26-
1.69) 
<0.001 
Education level      
Low 155(7.7) 137 (8.5) 1.13(0.88-
1.45) 
0.309  
Mid 663(32.9) 540 (33.5) 1.04(0.90-
1.20) 
0.532 
High 1200(59.5) 934 (58.0) 1  
Job situation      
Employed 1348(66.8) 1143 
(70.8) 
1  
Unemployed 136(6.7) 113 (7.0) 0.98(0.75-
1.27) 
0.879 
No Response 535(26.5) 358 (22.2) 0.78(0.670-
.92) 
0.003 
HIV test result in the previous 12 months       
No 1149(56.5) 802 (49.4) 1  
Yes 883(43.5) 882 (50.6) 1.33(1.17-
1.52) 
<0.001 
Ever been treated with PEP     
NO 1940(96.7) 1501 
(93.8) 
1  
Yes 20(1.0) 35 (2.2) 2.26(1.30-
3.93) 
0.004 
I don’t Know 46(2.3) 64(4.0) 1.79(1.22-
2.64) 
.003 
Having sex abroad with a man who was not from 
country of residence  
    
No 1228 (60.6) 877(54.2) 1  
Yes, more than 12month ago 483(23.9) 395(24.4) 1.14(0.97-
1.34) 
0.094 
Yes, in the last 12 months 314(15.5) 346(21.4) 1.54(1.29-
1.83) 
<0.001 
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Sex Venues: visited a social commercial venue in their 
country of residence: café, bar, disco, or nightclub  
    
Never 437(21.5) 229(14.1) 1  
Ever 1595(78.5) 1395(85.9) 1.66(1.40-
1.98) 
<0.001 
Ever tested for STIs      
Never tested for STIs other than HIV 1143(61.2) 807(53.8) 1  
Ever tested for STIs other than HIV 726(38.8) 692(46.2) 1.35(1.17-
1.54) 
<0.001 
Consumption of any drugs typically associated with 
sex and parties in the last 12 month  
    
Never/Before 12 Month 1614(80.0) 1232(77.0) 1  
In the last 12 Month 403(20.0) 369(23.0) 1.20(1.02-
1.40) 
0.025 
Predictors for the eligibility for HIV PrEP in non-Portuguese-born living in Portugal according to 
participants’ characteristics, results from EMIS 2010 
 Not 
Eligible 
Eligible  OR (CI) P.value 
Age      
<25 85(20.4) 88 (24.5) 1  
25-39 221(53.1) 191(53.2) 0.83(0.585-
1.19) 
0.319 
>or =40 110(26.4) 80(22.3) 0.70(0.46-
1.06) 
0.095 
Sexual Identity      
Bisexual/other 120(28.8) 97(27.2) 1  
Homosexual 296(71.2) 260(72.8) 1.08(0.79-
1.48) 
0.605 
Education level      
Low 26(6.3) 22(6.2) 1.08(0.59-
1.97) 
0.785 
Mid 124(30.1) 129(36.3) 1.33(0.98-
1.81) 
0.064 
High 262(63.6) 204(57.5) 1  
Job situation      
Employed 306(74.1) 252(70.8) 1  
Unemployed 24(5.8) 28(7.9) 1.41(0.80-
2.50) 
0.231 
No Response 83(20.1) 76(21.3) 1.11(0.78-
1.58) 
0.556 
HIV test result in the last 12 months     
No 206(49.5) 175(48.7) 1  
Yes 210(50.5) 184(51.3) 1.03(0.77-
1.36) 
0.830 
Ever been treated with PEP     
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NO 386(94.1) 328(92.7) 1  
Yes 8(2.0) 8(2.3) 1.17(0.43-
3.17) 
0.747 
I don’t Know 16(3.9) 18(5.1) 1.32(0.66-
2.63) 
0.425 
Having sex abroad with a man who was not from country 
of residence  
    
No 174(42.1) 119(33.3) 1  
Yes, more than 12month ago 121(29.3) 99(27.7) 1.19(0.84-
1.70) 
0.320 
Yes, in the last 12 months 118(28.6) 139(38.9) 1.72(1.22-
2.41) 
0.002 
Sex Venues: visited a social commercial venue in their 
country of residence: café, bar, disco, or nightclub  
    
Never 68(16.4) 30(8.4) 1  
Ever 347(83.6) 329(91.6) 2.14(1.36-
3.38) 
0.001 
Ever tested for STIs      
Never tested for STIs other than HIV 190(48.6) 168(50.0) 1  
Ever tested for STIs other than HIV 201(51.4) 168(50.0) 0.94(0.70-
1.26) 
<0.705 
Consumption of any drugs typically associated with sex 
and parties in the last 12 month  
    
Never/Before 12 Month 343(83.1) 279(79.7) 1  
In the last 12 Month 70(16.9) 71(20.3) 1.24(0.86-
1.79) 
0.237 
Predictors for the eligibility for HIV PrEP in Portuguese-born living abroad according to participants’ 
characteristics, results from EMIS 2010 
 Not 
Eligible 
Eligible  OR (CI) P.value 
Age      
<25 33(19.0) 23(16.1) 1  
25-39 112(64.4) 105(73.4) 1.34(0.74-
2.43) 
0.329 
>or =40 29(16.7) 15(10.5) 0.74(0.32-
1.68) 
0.476 
Sexual Identity      
Bisexual/other 44(25.3) 28(19.7) 1  
Homosexual 130(74.7) 114(80.3) 1.37(0.80-
2.35) 
0.241 
Education level     
Low 18(10.5) 19(13.5) 1.62(0.80-
3.31) 
0.170 
Mid 46(26.7) 52(36.9) 1.74(1.06-
2.86) 
0.029 
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Discussion: 
High-risk groups are one of the biggest obstacles toward eradication of the HIV 
infection. MSM and migrant are within the most vulnerable groups. Since the 
beginning of HIV epidemic in the early 80s, MSM are one of the main populations 
affected by the disease (32, 33). The present study used data from the EMIS to 
High 108(62.8) 70(49.6) 1  
Job situation      
Employed 136(79.0) 108(75.5) 1  
Unemployed 12(7.0) 17(11.9) 1.78(0.81-
3.89) 
0.146 
No Response 24(14.0) 18(12.6) 0.94(0.48-
1.83) 
0.865 
HIV test result in the last 12 months      
No 92(52.9) 54(37.8) 1  
Yes 82(47.1) 89(62.2) 1.84(1.17-
2.90) 
0.007 
Ever been treated with PEP     
NO 165(95.9) 133(94.3) 1  
Yes 5(2.9) 6(4.3) 1.48(0.44-
4.98) 
0.519 
I don’t Know 2(1.2) 2(1.4) 1.24(0.17-
8.92) 
0.830 
Having sex abroad with a man who was not from country 
of residence  
    
No 44(25.6) 35(24.5) 1  
Yes, more than 12month ago 56(32.6) 31(21.7) 0.696(0.37-
1.29) 
0.255 
Yes, in the last 12 months 72(41.9) 77(53.8) 1.344(0.77-
2.32) 
0.290 
Sex Venues: visited a social commercial venue in their 
country of residence: café, bar, disco, or nightclub  
    
Never 14(8.0) 15(10.5) 1  
Ever 160(92.0) 128(89.5) 0.74(0.34-
1.60) 
0.454 
Ever tested for STIs      
Never tested for STIs other than HIV 76(46.3) 69(50.7) 1  
Ever tested for STIs other than HIV 88(53.7) 67(49.3) 0.83(0.53-
1.32) 
0.449 
Consumption of any drugs typically associated with sex 
and parties in the last 12 month  
    
Never/Before 12 Month 151(86.8) 124(86.7) 1  
In the last 12 Month 23(13.2) 19(13.3) 1.00(0.52-
1.93) 
0.986 
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investigate the eligibility for HIV PrEP among MSM in Portugal. Our results revealed 
a high prevalence of eligibility for HIV PrEP. Since almost half of the participants in 
the 3 categories seem to be eligible for PrEP, attention to the question of how PrEP 
may affect the national HIV epidemic among MSM should be considered. Overall, the 
perception of difference in the proportions of eligible individuals among the 3 groups 
was not statistically significant, but after classifying migrants living in Portugal 
according to region of origin, we found that participants from Latin America and 
Caribbean were more likely to be eligible for PrEP in comparison to Portuguese-born 
(OR=1.27; 95%CI 1.04-1.58; p=0.023). Among migrants who were eligible for PrEP 
38.6% were from Latin America and Caribbean region. This finding can probably be 
explained by the substantial population of Brazilian migrants in Portugal. A study 
from Spain in a convenience sample of MSM in Catalonia found that immigrants from 
the same region of origin, Latin America, were more likely to have UAI in the 
previous 12 months, which is one of the eligibility criteria for PrEP, in comparison to 
the Spanish MSM (OR= 2.28; 95%CI 1.43-3.64; p= 0.001)(34). In studies conducted 
among MSM in the US, MSM from Latin America reported the higher rates of UAI, 
when compared to the other minority groups (35).This evidence supports that we are 
not only observing the effect of host country but also the effect of contextual 
specificities of the region of origin, which highlights the need of focusing on specific 
migrant populations according to their region of origin.  
 
Non-monogamous relations with UAI in the last 6 months accounts for 96.2% of the 
eligibility for PrEP in Portuguese-born living in Portugal, 93.3% in non-Portuguese-
born living in Portugal, and 93.0% of the Portuguese-born living abroad. Since PrEP 
is not a sole intervention and it should be prescribed as part of a comprehensive 
prevention plan (5) that encompasses emphasis on condom use. Even though lack 
of consistent use of barrier protection is not a contraindication to PrEP(5). 
 
Among migrant MSM living in Portugal, participants who reported having sex abroad 
with a man who was not from the country of residence in the previous 12 month were 
more likely to be eligible (OR=1.72; 95%CI 1.22-2.41; p= 0.002). A study from 
Belgium found that MSM residing in Belgium who had sexual contact abroad were 
more likely to be also expatriates too (36).  
 
The final results from the EMIS total European sample showed that, and compared 
with non-migrants, migrants were more likely to be over 25 years of age, to live in a 
large city, have a higher university degree, be more open about their sexual 
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orientation and feel lonely (27). Moreover, migrants use more drugs associated with 
sex and parties, more usually reported having more partners in the last 12 months, 
and more likely to be diagnosed with HIV/STIs in the last 12 months (27). Different 
cultures and strains in adapting into the country of residence may contribute to higher 
risk behavior among migrant MSM (27). Associations were found between certain 
types of risk behavior that might increase the danger of their acquiring HIV infection 
and STIs among migrant MSM (27). The study concluded that, a greater self-
reported prevalence of HIV and STIs among migrant MSM together with lesser 
access to free or affordable HIV and STI testing services proposes that prevention 
interventions should be customized and tailored for this category (27). Social and 
community support could be included in these specific interventions since studies 
established an association between social isolation and sexual risk behaviour among 
MSM (27).   
 
On the other hand, our Portuguese study sample study showed that Portuguese-born 
living in Portugal showed the highest number of predictors for eligibility in comparison 
to non-Portuguese-born living in Portugal (migrants) and Portuguese-born living 
abroad. Portuguese official surveillance data showed an annual 9% increase in the 
number of newly diagnosed cases of HIV among MSM from 2005 to 2102, while 
there was a decrease by 2% in the new cases due to heterosexual intercourse and 
decrease by 18% in new cases due to unsafe injection behavior(37, 38). The 
proportion of MSM among all HIV cases diagnosed in 2013 amounted to 42.9 % 
while MSM represent approximately 3% of the male adult population(37, 38). This 
means that existing approaches to prevention have failed to control the HIV epidemic 
among MSM in Portugal; accordingly PrEP can be an additional new effective 
intervention against HIV infection in MSM that can control and curb the infection 
among MSM in Portugal. 
 
Among Portuguese-born living in Portugal, consumption of any reactional drugs in 
the last 12 months showed a clear association with the eligibility for the PrEP, that 
was in line with several studies that showed an association between unprotected 
sexual relation, and the use of drugs (39-41). All of that highlights the crucial need to 
include drugs and substance use in any prevention program if we would like to avoid 
or decrease PrEP use among the target population. 
 
The same category showed a strong association between PrEP and being ever 
tested for STDs other than HIV and the eligibility for HIV PrEP. That makes 
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prevention and screening programs that address STDs in MSM of paramount 
important. Some MSM avoid seeking healthcare because they expect disapproval 
regarding their lifestyle (42), this behavior can be exaggerated in certain populations 
such as migrants due to some cultural barriers and stigma, so it is particularly 
important for the healthcare personnel to become culturally competent toward this 
issues. This highlights the need for establishing screening programs for STDs that 
can play a crucial role in the early diagnosis of STDs and decrease the transmission.  
 
Limitations: 
 
Taking into consideration the self-reported nature of the survey, limitations such as 
social desirability bias and recall bias may affect some findings. Exclusion of MSM 
who don’t have an access to the Internet, who may show different socio-
demographic characteristics, make the data biased toward participants with higher 
level of education and an access to the internet. The social desirability bias and the 
bias of data toward participants with higher education level may therefore have 
influenced the results in that it underestimates levels of eligibility for HIV PrEP, but 
despite this type of biases, this is the largest sample of MSM ever studied in 
Portugal. Although being Internet-based survey which recruited participants through 
internet and individuals in such samples tend to be more educated, urban and 
younger, EMIS was able to recruit the world’s largest sample of MSM, including 
about 180,000 MSM from 38 countries. In addition, this is the largest study to date to 
examine not only the proportions of eligible individuals but also the predictors of 
eligibility for PrEP among MSM in Portugal. This research represents an important 
step in investigating the proportion of eligible individuals for HIV PrEP in the largest 
sample of MSM ever studied in Portugal. 
 
 Conclusion:  
 
No differences were found for PrEP eligibility between the three groups, but the 
predictors for PrEP were different among them. Accordingly, further analysis of the 
predictors in each category will help to customize tailored prevention programs for 
each group. Moreover, additional subgroup analysis of migrant MSM in Portugal is 
mandatory to address migration experiences and determine which migrant 
population needs more support. Further analysis of migration and mobility is needed, 
taking into consideration a more advanced definition of migrant and mobility 
dynamics. 
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Conclusion: 
 
• No differences were found for PrEP eligibility between the three groups, but 
the predictors for PrEP were different among them. Accordingly, further 
analysis of the predictors in each category will help to customize tailored 
prevention programs for each group. A 
 
• Additional subgroup analysis of migrant MSM in Portugal is mandatory to 
address migration experiences and determine which migrant population 
needs more support. Further analysis of migration and mobility is needed, 
taking into consideration a more advanced definition of migrant and mobility 
dynamics. 
 
• In the light of the high proportions of eligibility for HIV PrEP within the 3 
groups, there is a necessity for moving from research in to policy, 
management and practical application, and for integration of research and 
policy to acquire a comprehensive implementation framework for PrEP in 
Portugal. It is essential for public health decision makers to formulate a 
collective, coordinated and rational response to the results of the last official 
reports that showed substantial burden of HIV among MSM in Portugal. 
 
• Because pills alone will never entirely control the HIV epidemic among MSM 
in Portugal, we also need an effective combination prevention approaches 
that may combine PrEP with other prevention strategies and to combine PrEP 
with behavioral and social interventions to curb down HIV incidence in MSM 
in Portugal. 
 
• The high transmission for HIV in MSM proposes that prevention methods that 
can decrease possibilities of per-act transmission such as PrEP will possibly 
be needed in a population-based national level, to produce considerable 
reductions in new infections and to produce substantial results.  
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